Cover Image
Market Research Report
Product code 
1081112

U.S. Market Study on Respiratory Syncytial Virus Vaccines: Upcoming Launch of Cost-effective Candidates to Drive Market Growth

Published: | Persistence Market Research | 134 Pages | Delivery time: 2-3 business days

Price

Back to Top
U.S. Market Study on Respiratory Syncytial Virus Vaccines: Upcoming Launch of Cost-effective Candidates to Drive Market Growth
Published: April 13, 2022
Persistence Market Research
Content info: 134 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents
  • List of Tables

U.S. Respiratory Syncytial Virus Vaccines Market: Scope of Report

The latest publication by Persistence Market Research on the U.S. respiratory syncytial virus vaccines market evaluates the opportunities and current market landscape and provides detailed analysis and updates about corresponding sections affecting the market. The study offers detailed insights on current market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2022-2032.

Important indicators for the successful growth of the market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in Persistence Market Research's study. This research study can support readers to know the demand for respiratory syncytial virus vaccines products in the U.S. and the quantitative development opportunities during the study period.

The research is beneficial for shareholders in the landscape, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the U.S. respiratory syncytial virus vaccines market. Insights and information presented in this Persistence Market Research study can be leveraged by shareholders in the U.S. respiratory syncytial virus vaccines market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.

Market statistics, as well as information linked to the macro- as well as micro-economic variables affecting the business scenario in the respiratory syncytial virus vaccines market, are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.

Key Market Segments

Persistence Market Research's study on the U.S. respiratory syncytial virus vaccines market offers information divided into two important segments - drug and distribution channel. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Drug

Palivizumab

RSVpreF PF06928316

RSVPreF3 OA (GSK3844766A)

mRNA-1345

mRNA-1345

Janssen RSV Vaccine

ResVax

Nirsevimab (MEDI8897)

MVA-BN RSV

Distribution Channel

Institutional Sales

Hospitals

Specialty Clinics

Academic and Research Institutes

Retail Sales

Retail Pharmacy

Drug Stores

Online Sales

Key Questions Answered in Report

Which regions will continue to remain the most profitable markets for respiratory syncytial virus vaccines in the U.S. over the coming years?

How will changing trends impact the market?

How has the COVID-19 crisis impacted market growth?

How can market players capture the low-hanging opportunities in developed regions?

What are the strategies of stakeholders in the market to shape their position in this landscape?

What are the restraining factors that investors need to be aware of and might tackle while investing in the market?

What are the developmental trends that will impact the market?

How can companies in the respiratory syncytial virus vaccines market avail themselves the growth opportunities in developed and emerging sectors?

Research Methodology

In Persistence Market Research's study, a unique research methodology is utilized to conduct extensive research on the growth of the U.S. respiratory syncytial virus vaccines market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts to ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as validation from companies in the market, and makes Persistence Market Research's projections on the growth prospects of the U.S. respiratory syncytial virus vaccines market are more accurate and reliable.

Product Code: PMRREP33045

Table of Contents

1. Executive Summary

  • 1.1. U.S. Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusion and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Application Innovation / Development Trends

4. Key Success Factors

  • 4.1. Disease Epidemiology
  • 4.2. Key Promotional Strategies
  • 4.3. Key Regulations
  • 4.4. Value Chain Analysis
  • 4.5. Pipeline Analysis
  • 4.6. Recommendations for RSV
  • 4.7. PESTLE Analysis
  • 4.8. PORTER Analysis

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. U.S. GDP Growth Outlook
    • 5.1.2. U.S. Healthcare Expenditure Outlook
    • 5.1.3. Research & Development Funding
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Rising Life Science research and development activities
    • 5.2.2. Disease Epidemiology
    • 5.2.3. Treatment Adoption Analysis
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. U.S. Respiratory Syncytial Virus Vaccines Market Demand Value (US$ Mn) Analysis 2017-2021 and Forecast, 2022-2032

  • 6.1. Historical Market Value (US$ Mn) Analysis, 2017-2021
  • 6.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032
    • 6.2.1. Y-o-Y Growth Trend Analysis
    • 6.2.2. Absolute $ Opportunity Analysis

7. U.S. Respiratory Syncytial Virus Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Drug Type

  • 7.1. Introduction / Key Findings
  • 7.2. Historical Market Value (US$ Mn) By Drug Type , 2017-2021
  • 7.3. Current and Future Market Value (US$ Mn) Analysis and Forecast By Drug Type , 2022-2032
    • 7.3.1. Palivizumab
    • 7.3.2. RSVpreF PF06928316
    • 7.3.3. RSVPreF3 OA (GSK3844766A)
    • 7.3.4. mRNA-1345
    • 7.3.5. mRNA-1345
    • 7.3.6. Janssen RSV Vaccine
    • 7.3.7. ResVax
    • 7.3.8. Nirsevimab (MEDI8897)
    • 7.3.9. MVA-BN RSV

8. U.S. Respiratory Syncytial Virus Vaccines Market Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel

  • 8.1. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2017-2021
  • 8.2. Current and Future Market Material (US$ Mn) Analysis and Forecast By Distribution Channel, 2022-2032
    • 8.2.1. Institutional Sales
      • 8.2.1.1. Hospitals
      • 8.2.1.2. Specialty Clinics
      • 8.2.1.3. Academic and Research Institutes
    • 8.2.2. Retail Sales
      • 8.2.2.1. Retail Pharmacy
      • 8.2.2.2. Drug Stores
    • 8.2.3. Online Sales

9. Competition Analysis

  • 9.1. Competition Dashboard
  • 9.2. Competition Deep Dive
    • 9.2.1. Pfizer Inc.
      • 9.2.1.1. Overview
      • 9.2.1.2. Service Portfolio
      • 9.2.1.3. Key Financials
      • 9.2.1.4. Strategy Overview
    • 9.2.2. Sanofi
      • 9.2.2.1. Overview
      • 9.2.2.2. Service Portfolio
      • 9.2.2.3. Key Financials
      • 9.2.2.4. Strategy Overview
    • 9.2.3. Merck Sharp & Dohme
      • 9.2.3.1. Overview
      • 9.2.3.2. Service Portfolio
      • 9.2.3.3. Key Financials
      • 9.2.3.4. Strategy Overview
    • 9.2.4. GlaxoSmithKline
      • 9.2.4.1. Overview
      • 9.2.4.2. Service Portfolio
      • 9.2.4.3. Key Financials
      • 9.2.4.4. Strategy Overview
    • 9.2.5. SOBI
      • 9.2.5.1. Overview
      • 9.2.5.2. Service Portfolio
      • 9.2.5.3. Key Financials
      • 9.2.5.4. Strategy Overview
    • 9.2.6. Johnson & Johnson
      • 9.2.6.1. Overview
      • 9.2.6.2. Service Portfolio
      • 9.2.6.3. Key Financials
      • 9.2.6.4. Strategy Overview
    • 9.2.7. Bavarian Nordic
      • 9.2.7.1. Overview
      • 9.2.7.2. Service Portfolio
      • 9.2.7.3. Key Financials
      • 9.2.7.4. Strategy Overview
    • 9.2.8. Novavax
      • 9.2.8.1. Overview
      • 9.2.8.2. Service Portfolio
      • 9.2.8.3. Key Financials
      • 9.2.8.4. Strategy Overview
    • 9.2.9. AstraZeneca
      • 9.2.9.1. Overview
      • 9.2.9.2. Service Portfolio
      • 9.2.9.3. Key Financials
      • 9.2.9.4. Strategy Overview
    • 9.2.10. Moderna, Inc.
      • 9.2.10.1. Overview
      • 9.2.10.2. Service Portfolio
      • 9.2.10.3. Key Financials
      • 9.2.10.4. Strategy Overview
    • 9.2.11. Codagenix Inc.
      • 9.2.11.1. Overview
      • 9.2.11.2. Service Portfolio
      • 9.2.11.3. Key Financials
      • 9.2.11.4. Strategy Overview
    • 9.2.12. Intravacc BV.
      • 9.2.12.1. Overview
      • 9.2.12.2. Service Portfolio
      • 9.2.12.3. Key Financials
      • 9.2.12.4. Strategy Overview
    • 9.2.13. Alphavax, Inc.
      • 9.2.13.1. Overview
      • 9.2.13.2. Service Portfolio
      • 9.2.13.3. Key Financials
      • 9.2.13.4. Strategy Overview

10. Assumptions and Acronyms Used

11. Research Methodology

List of Tables

  • Table 01: U.S. Respiratory Syncytial Virus (RSV) Vaccines Market Size (US$ Mn) Analysis 2017-2021 and Forecast, 2022-2032, By Drug Type
  • Table 02: U.S. Respiratory Syncytial Virus (RSV) Vaccines Market Size (US$ Mn) Analysis 2017-2021 and Forecast 2022-2032, By Distribution Channel

List of Figures

  • Figure 01: U.S. Respiratory Syncytial Virus (RSV) Vaccines Market size (US$ Mn) 2022E & 2032F
  • Figure 02: U.S. Respiratory Syncytial Virus (RSV) Vaccines Market Size (US$ Mn) Analysis, 2017-2021
  • Figure 03: U.S. Respiratory Syncytial Virus (RSV) Vaccines Market Size (US$ Mn) & Y-o-Y Growth (%), Analysis, 2022-2032
  • Figure 04: U.S. Respiratory Syncytial Virus (RSV) Vaccines Market Absolute $ Opportunity Analysis, 2022-2032